Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3904 | Talabostat Mesylate plus Pembrolizumab Wiki | 1.00 |
| drug1030 | Control Wiki | 0.28 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018288 | Carcinoma, Small Cell NIH | 1.00 |
| D055752 | Small Cell Lung Carcinoma NIH | 0.71 |
| D018358 | Neuroendocrine Tumors NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030357 | Small cell lung carcinoma HPO | 0.71 |
| HP:0100634 | Neuroendocrine neoplasm HPO | 0.58 |
| HP:0012125 | Prostate cancer HPO | 0.45 |
Navigate: Correlations HPO
There is one clinical trial.
This will be a randomized control trial assessing the impact of CRI:SIS as a simulation-based preparedness intervention on physician stress levels through changes to heart rate variability (HRV) on shift while caring for COVID-19 patients and post-shift anxiety as measured by the State-Trait Anxiety Inventory (STAI ). The aim is to test CRI:SIS to determine its effect on mitigating physician stress on shift and anxiety post-shift related to provision of COVID-19 care
Description: The change in physician end-of-shift heart rate variability will be measured using the Hexoskin Smart Shirt. The Hexoskin shirt contains three sensors to capture participant heart rate via ECG, respiratory rate, minute ventilation, and movement/activity. Changes in HRV will be averaged over the two post-intervention shift data collections to control for an anticipated shift-to-shift and patient-to-patient variability in stress response due to patient acuity and workload
Measure: Change in end-of-shift heart rate variability Time: Baseline, 5 minutes post-intervention shiftDescription: The change in physician end-of-shift anxiety measured by the State-Trait Anxiety Inventory (STAI) for physicians exposed to the simulation based training preparation compared to standard guideline update delivery. Each STAI item is given a weighted score of 1 to 4. A rating of 4 indicates the presence of a high level of anxiety for items (e.g., "I feel frightened," "I feel upset"). To obtain scores for the S-Anxiety, simply add the weighted scores for the twenty items that make up the scale, taking into account the fact that the scores are reversed for specific items. Scores for the S-Anxiety scale can vary from a minimum of 20 to a maximum of 80.
Measure: Change in STAI S-Anxiety Time: Baseline, 5 minutes post-intervention shiftDescription: The secondary outcome of interest is change in anxiety between the intervention and control conditions as measured by the State-Trait Anxiety Inventory (STAI). The T-Anxiety scale (STAI Form Y-2) consists of twenty statements that assess how people generally feel. The scoring weights for the anxiety-present items are the same as the chosen numbers on the print inventory form. To obtain scores for the T-Anxiety scale, simply add the weighted scores for the twenty items that make up the scale, taking into account the fact that the scores are reversed for specific items. Scores for the T- Anxiety scales can vary from a minimum of 20 to a maximum of 80.
Measure: Change in STAI T-Anxiety Time: Baseline, 1 weekAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports